CXCR4 and hepatocellular carcinoma: Targeting CXCR4 with AMD3100 also prevents the polarization toward an immunosuppressive microenvironment after sorafenib treatment, suppresses HCC tumor growth, reduces metastasis and improves survival (Chen et al., 2015).